Bioconversion of compactin into pravastatin by Streptomyces sp
Related Experiment Video
Updated: Aug 29, 2026

Genetic Engineering of an Unconventional Yeast for Renewable Biofuel and Biochemical Production
Published on: September 20, 2016
Joo-Woong Park1, Joo-Kyung Lee, Tae-Jong Kwon
1Biotechnology Laboratory, Youngjin Pharmaceutical Co. Ltd., Pyungtaek-Si 451-860, Korea.
Abstract:
Streptomyces sp. Y-110, isolated from soil, modified compactin to pravastatin, a therapeutic agent for hypercholesterolemia. In a batch culture, the highest production of pravastatin was 340 mg l(-1) from 750 mg compactin l(-1) in 24 h. By intermittent feeding of compactin into the culture medium, both the compactin concentration and its conversion increased to 2000 mg l(-1) and 1000 mg pravastatin l(-1), respectively, with the conversion rate of 10 mg l(-1) h(-1). Continuous feeding of compactin increased production of pravastatin to 15 mg l(-1) h(-1).
More Related Videos
09:08From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes Tü6028
Published on: January 13, 2017
07:59A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products
Published on: October 4, 2019
Related Concept Videos
Production of Antibiotics
Production of Pharmaceuticals
Upstream Processing
Bioreactor Controls-III
Production of Organic Acids